177Lu-LNCAb103
/ National University of Singapore
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
June 13, 2025
Radiolabeled engineered antibody 177Lu-LNCAb103 as HER2 targeting cancer theranostics
(SNMMI 2025)
- "177Lu-LNCAb103 had high radiochemical purity and good stability over time, and showed a favorable HER2 binding affinity and targeting specificity in vitro. SPECT/CT imaging of 177Lu-LNCAb103 exhibited remarkably high tumor uptake and retention up to 96 h. Compared with 177Lu-traustuzumab, 177Lu-LNCAb103 showed higher tumor-to-background ratio and lower blood uptake. Drug distribution half-lives (1.43±1.30 h vs."
Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
June 13, 2025
Radiolabeled engineered antibody 177Lu-LNCAb103 as HER2 targeting cancer theranostics
(SNMMI 2025)
- "177Lu-LNCAb103 had high radiochemical purity and good stability over time, and showed a favorable HER2 binding affinity and targeting specificity in vitro. SPECT/CT imaging of 177Lu-LNCAb103 exhibited remarkably high tumor uptake and retention up to 96 h. Compared with 177Lu-traustuzumab, 177Lu-LNCAb103 showed higher tumor-to-background ratio and lower blood uptake. Drug distribution half-lives (1.43±1.30 h vs."
Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
June 17, 2025
PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors
(clinicaltrials.gov)
- P1 | N=10 | Enrolling by invitation | Sponsor: Affiliated Hospital of Jiangnan University
New P1 trial • Breast Cancer • Gastric Cancer • Oncology • Solid Tumor • Urothelial Cancer
May 11, 2025
Radiolabeled engineered antibody 177Lu-LNCAb103 as HER2 targeting cancer theranostics
(SNMMI 2025)
- "177Lu-LNCAb103 had high radiochemical purity and good stability over time, and showed a favorable HER2 binding affinity and targeting specificity in vitro. SPECT/CT imaging of 177Lu-LNCAb103 exhibited remarkably high tumor uptake and retention up to 96 h. Compared with 177Lu-traustuzumab, 177Lu-LNCAb103 showed higher tumor-to-background ratio and lower blood uptake. Drug distribution half-lives (1.43±1.30 h vs."
Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
1 to 4
Of
4
Go to page
1